Objectives: Carbapenemase-producing Enterobacteriaceae are important nosocomial pathogens in many medical centres. Surveillance is needed to track trends and detect emergence of new carbapenemases.
Introduction
The emergence of carbapenemase-producing Enterobacteriaceae (CRE) has been declared an 'urgent' and 'critical' threat by national and international organizations. Two decades ago, Enterobacteriaceae possessing the b-lactamase KPC emerged in New York City hospitals 1 and today have become a global threat. In the USA, KPCs account for 88% of the carbapenemases found in CRE and Klebsiella pneumoniae is the predominant pathogen. 2 Treatment options are extremely limited and mortality rates are high in patients infected with CRE. Interventions to reduce the spread of CRE have been developed and reports of containment of these pathogens on the local and national level have been documented. [2] [3] [4] Reasons for successful containment are probably multifactorial and include improved detection methods, heightened infection control efforts and a reduction in use of devices. [2] [3] [4] Residents of long-term care facilities are increasingly recognized as being at risk of colonization with KPC-producing bacteria. 5 Residents of skilled nursing facilities with ventilatory care units and long-term acute care facilities are at increased risk, with up to 30% of residents colonized with KPC-producing bacteria. 5 A bundled intervention, including screening for colonization, cohorting and selective universal contact isolation, plus daily bathing with 2% chlorhexidine gluconate, was associated with significant reduction in colonization and infection with KPC-producing bacteria. 6 In this report, we describe the prevalence of KPC-producing pathogens in seven acute care New York City hospitals and the emergence of a new carbapenemase.
Materials and methods
During a 3 month period in the spring of 2017, unique-patient isolates of Escherichia coli, K. pneumoniae and Enterobacter spp. were collected from seven hospitals in Brooklyn, NY, USA. As in prior surveillance studies, only clinical isolates were gathered over the 3 month period. 3, 7, 8 Susceptibility testing was performed with the agar dilution method and interpreted according to CLSI standards. 9 Isolates with a polymyxin B MIC of 2 mg/L were considered susceptible. Results were compared with similar studies conducted in 2006, 2009 and 2013-14. 3,7 All cephalosporin-resistant isolates were screened, using previously described primers and PCR conditions, for the presence of the following carbapenemase genes: bla KPC , bla IMP , bla VIM and bla OXA-48 . 1, 10, 11 In addition, isolates were screened for bla NDM using the following primers: NDMf 5 0 -CCAATATTATGCACCCGGTC-3 0 and NDMr 5 0 -TAGTGCTCAGTGTCGGCATC-3 0 . Selected isolates were screened for the presence of bla SHV , bla TEM and bla CTX-M -type b-lactamases, as previously described. ATATCGTTGGTGGTG-3 0 . Genes encoding porins for selected isolates of E. coli and K. pneumoniae were amplified using previously described primers 13, 14 and translations were compared with porins of E. coli ATCC 29522 and WT K. pneumoniae. 15 Genes encoding aminoglycoside-modifying enzymes were detected using previously identified primers and conditions. 16 Plasmids were extracted using a QIAGEN Miniprep kit (QIAGEN, Valencia, CA, USA). Isolates of KPC-producing K. pneumoniae and selected isolates of E. coli underwent MLST using established primers and conditions. 17 
Results and discussion

Multi-hospital surveillance study
A total of 2619 unique-patient isolates were gathered during the surveillance study, including 1911 E. coli, 533 K. pneumoniae and 175 Enterobacter spp. (Table 1 ). More than 95% were susceptible to meropenem and all were susceptible to ceftazidime/avibactam. A total of 28 isolates were found harbouring bla KPC , including 3 E. coli (0.2%), 22 K. pneumoniae (4.1%) and 3 Enterobacter spp. (1.7%). No other carbapenemases were detected in the surveillance isolates. Of the 22 isolates of K. pneumoniae with bla KPC , 12 were ST258 and 4 were closely related to ST258 (ST340 and ST3359). Two isolates belonged to ST15 and one each belonged to ST45, ST327, ST584 and ST3369.
At hospital D, there were seven KPC-possessing K. pneumoniae recovered. Five of the seven isolates were from outpatients, including four who were residents at three different long-term care facilities and one was a patient recently discharged from a neighbouring acute care medical centre. The remaining two isolates were considered hospital-onset infections, although one patient was also a resident at a long-term care facility prior to admission. Of the five isolates from outpatients, two were ST258, one was ST340 and two were unrelated. The two hospital-onset isolates were both ST340.
Compared with prior surveillances, there has been a steady decline in the percentage of K. pneumoniae isolates harbouring bla KPC (Table 2) 
Emergence of NDM-5 Case 1
In January 2018, a patient with multiple medical problems, including dementia and stage IV decubitus ulcers, was admitted to hospital D for severe sepsis. The patient was a resident of a skilled nursing facility located in New York City. Admission blood cultures grew carbapenem-resistant E. coli and urine culture yielded carbapenem-resistant K. pneumoniae. Both isolates were susceptible to polymyxin B (MICs 1 mg/L) and resistant to ceftazidime/avibactam (MICs .256 mg/L by Etest). The patient was successfully treated with a 14 day course of a polymyxin B-based regimen. Both E. coli and K. pneumoniae isolates carried bla NDM-5 and bla CTX-M-15 ; bla TEM-1 and bla SHV-28 were also present in the K. pneumoniae isolate. No other carbapenemases were recovered. The isolate of E. coli had multiple changes in OmpC, including an eight amino acid deletion (del134 NDPDFTGH 141) and a seven amino acid insert (ins189 NGYGERY 190). Three mutations were present in OmpF: N52D, S226P and E306D. For the isolate of K. pneumoniae, ompK35 could not be amplified and OmpK36 contained multiple changes including a three amino acid insert (ins183 LSP 184) and a single amino acid insert (ins 226 S 227). This isolate of K. pneumoniae belonged to ST15.
Case 2
In February 2018, a resident of the same skilled nursing facility was admitted to hospital C for sepsis and respiratory distress. The patient had advanced dementia and underlying COPD. A rectal surveillance culture was obtained on admission and grew a carbapenem-resistant E. coli. This isolate was also susceptible to polymyxin B (MIC 1 mg/L) and resistant to ceftazidime/avibactam (MIC .256 mg/L by Etest). The isolate also carried bla NDM-5 and bla CTX-M-15 .
The two E. coli NDM-possessing isolates from hospitals C and D belonged to the same sequence type (ST43). The genes bla NDM-5 and bla CTX-M-15 , along with aacA4 and aadA1, were found on a plasmid recovered from the three NDM-possessing isolates.
KPC-possessing K. pneumoniae were first identified in New York City in 1997 and within 10 years 38% of isolates carried this Iregui et al.
carbapenemase. 1, 8 Since 2006, there has been a steady decline in the percentage of KPC-producing K. pneumoniae isolates in our acute care medical centres. There has been a decline in ceftazidime-resistant (i.e. ESBL-possessing) isolates over the past decade as well that could not be solely accounted for by the decline in carbapenemase-producing strains. Most of our carbapenem-resistant isolates belonged to ST258 (or closely related sequence types), which is the predominant strain with bla KPC . As previously noted, the reason for the decline in carbapenem-and cephalosporin-resistant isolates is likely multifactorial. 3, 4, 6 Bundled interventions that typically include screening for asymptomatic carriers, baths with chlorhexidine gluconate and heightened infection control precautions, have likely contributed to this decline. 6, 7 In addition, the decline in device utilization, along with central line bloodstream infections and urinary catheter infections, has paralleled the decline in cephalosporin-and carbapenem-resistant Enterobacteriaceae and is likely another contributing factor. 2, 3 It is uncertain whether the development of antimicrobial stewardship programmes over the past decade has been a factor. 3 While reductions in KPC-producing Enterobacteriaceae have been documented in acute care medical centres, it appears patients at skilled nursing facilities are important reservoirs for KPC-producing bacteria. Coordinated interventions, guided by governmental health departments, will be necessary to interrupt the transfer of these resistant pathogens from long-term care facilities to acute care medical centres.
While the persistent decline in KPC-producing K. pneumoniae in New York City hospitals is encouraging, the emergence of NDM-5 is obviously disconcerting. NDM-type carbapenemases have been distinctly unusual in the USA. 2 The NDM-5 b-lactamase has been predominantly reported from Asia and Europe; 18, 19 a single imported case has been described in the USA. 20 The finding of bla NDM-5 -producing E. coli in two patients from the same skilled nursing facility suggests unrecognized spread of this b-lactamase. Treatment options for NDM-possessing Enterobacteriaceae are extremely limited, as they are resistant to the newer b-lactam/b-lactamase inhibitor antibiotics (ceftazidime/avibactam and meropenem/vaborbactam). This carbapenemase would have likely remained unrecognized had not the resistance to ceftazidime/avibactam been identified. Local health department authorities were alerted to these findings and their investigation is pending. In the absence of molecular testing, we believe testing susceptibility to ceftazidime/ avibactam and/or meropenem/vaborbactam should be performed on all CRE.
In New York City, the carbapenemase landscape continues to evolve. Continued real-time vigilance involving both acute and long-term care medical centres, as suggested by the CDC's Antibiotic Resistance Laboratory Network, will be necessary to identify and limit the spread of MDR Enterobacteriaceae. 
